Unlocking the Future of the GM1 Gangliosidosis Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the gm1 gangliosidosis market?
In recent times, there has been a swift expansion in the GM1 gangliosidosis market. Projected to rise from $0.51 billion in 2024 to $0.57 billion in 2025, the market anticipates an 11.4% compound annual growth rate (CAGR). This significant growth during the past period is credited to the escalating number of patients battling with gm1 gangliosidosis, the increasing interest in the gm1 gangliosidosis area, a surge in awareness regarding rare diseases, the rising trend of patient-driven research, and enhanced attention towards early intervention.
What will be the gm1 gangliosidosis market size in the future?
Expectations are high for substantial expansion in the GM1 gangliosidosis market over the next few years. With a projected compound annual growth rate (CAGR) of 11.1%, the market could potentially realize a value of $0.87 billion by 2029. Factors contributing to this growth forecast include a rising incidence of gm1 gangliosidosis, an increase in lysosomal storage disorder cases, more clinical trials, growing emphasis on gene therapy and editing, increased interest in personalized and precision medicine, and a rising interest in genetic screening programs. Future trends predicted to impact the market include technological advancements in gene editing, the use of technology in healthcare settings, diagnostic technique advancements, improved formulations, and progress in genetic therapies.
Get your gm1 gangliosidosis market report here!
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report
What main drivers are fueling expansion in the gm1 gangliosidosis market?
The GM1 gangliosidosis market is expected to expand, fueled by the escalating utilization of gene therapy. Gene therapy, a vital medical remedy, operates by modifying or substituting specific genes in an individual’s cells to reduce or prevent diseases. Its growing adoption is spurred by strides made in genetic research, successful treatment results for conditions previously deemed untreatable, and burgeoning regulatory backing for innovative therapies. In the case of GM1 gangliosidosis, gene therapy entails delivering an operative version of the defective gene (GLB1) to the patient’s cells to revive ß-galactosidase enzyme functionality and lessen toxic substrate accumulation. For instance, as reported by American Society of Gene & Cell Therapy, a U.S based non-profit medical and scientific organization, there was a 10 percent increment in phase III gene therapy clinical trials in the fourth quarter of April 2024. This marked the first quarterly hike since the third quarter of 2022. Therefore, the escalating adoption of gene therapy is steering the expansion of the GM1 gangliosidosis market.
What key areas define the segmentation of the global gm1 gangliosidosis market?
The GM1 gangliosidosis market covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy
3) By End-User: Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp
Who are the dominant players expanding their reach in the gm1 gangliosidosis market?
Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.
What are the key trends shaping the future of the gm1 gangliosidosis market?
Key players in the GM1 gangliosidosis marketplace are leveraging strategic alliances to maintain their market standing. Such partnerships are pivotal in propelling gene therapy advancements by marrying expertise, resources, and technology to hasten research, clinical trials, and product commercialization. In particular, in October 2024, US firm GEMMA Biotherapeutics Inc. collaborated with the Brazil-based health research body, Oswaldo Cruz Foundation (Fiocruz), to pioneer gene therapies for rare conditions, including GM1 gangliosidosis. The terms of the deal entailed Fiocruz investing up to $100 million for clinical research and production, targeting to make these sophisticated therapies available via Brazil’s public health system. This partnership underscores technology transfer and seeks to universalize accessibility to treatments hitherto available only to the wealthier demographics.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194
Which regions are emerging as leaders in the gm1 gangliosidosis market?
North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Osteoporosis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report
Postmenopausal Osteoporosis Treatment Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
